<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01859728</url>
  </required_header>
  <id_info>
    <org_study_id>GAMBIT201201</org_study_id>
    <nct_id>NCT01859728</nct_id>
  </id_info>
  <brief_title>GAMBIT Trial: Cisplatin Plus Irinotecan in the Treatment of Gallbladder or Biliary Tract Cancer</brief_title>
  <acronym>GAMBIT</acronym>
  <official_title>GAMBIT Trial: A Randomized,Non-comparative, Open-label Clinical Trial Evaluating Cisplatin Plus Irinotecan in the Treatment of Gallbladder or Biliary Tract Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital de Cancer de Barretos - Fundacao Pio XII</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Barretos Cancer Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate safety and efficacy of the combination cisplatin plus irinotecan in the treatment
      of biliary tract cancer.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>Up to 24 weeks from randomization</time_frame>
    <description>The overall response rate will measure the number of subjects with complete or partial response as best response during the entire treatment, over the total number of subjects, for each arm. The response will be evaluated according to RECIST 1.1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>6mo after the last enrolled patient</time_frame>
    <description>We will measure the number of subjects without progressive disease (complete response, partial response or stable disease) or any-cause death, whichever came first. For each patient, PFS will be calculated from randomization until progressive disease. Disease progression means radiologic progression per RECIST 1.1 or any-cause death. PFS will also be analysed with log-rank test, and reported as HR with respective 95% CI and p value, and median PFS will be estimated with kaplan-meyer method. All calculations will be performed 6 months after the last patient recruited. Also, the PFS rate at one and two years will be calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>6mo after the last enrolled patient</time_frame>
    <description>We will measure the number of subjects without any-cause death. For each patient, OS will be calculated from randomization until death. OS will also be analysed with log-rank test, and reported as HR with respective 95% CI and p value, and median OS will be estimated with kaplan-meyer method. All calculations will be performed 6 months after the last patient recruited. Also, the survival rate at one and two years will be calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate</measure>
    <time_frame>Up to 6 weeks from randomization</time_frame>
    <description>The disease control rate will measure the number of subjects with complete or partial response, or disease stabilization as best response during the entire treatment, over the total number of subjects, for each arm. The response will be evaluated according to RECIST 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>6 mo after the last enrolled patients</time_frame>
    <description>Safety and tolerability will be assessed using NCI CTCAE v3. The number of patients in each arm experiencing any grade Adverse Events (for each AE) and Serious AE (SAE) over the total number of subjects will be measured, and the proportion of patients experiencing AE in each arm will be compared using uncorrected chi-sq test. AE will be recorded in baseline and in each visit, and the worst grade AE will be considered. Each AE will be classified in grades 1-2, 3-4 and SAE.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Biomarker evaluation</measure>
    <time_frame>Baseline</time_frame>
    <description>The following biomarkers will be tested by immunohistochemistry: human equilibrative nucleoside transporter (hENT), X-ray repair cross-complementing protein 1 (XRCC1), Excision repair cross-complementing rodent repair deficiency, complementation group 1 (ERCC1) e mLH1. Then we will correlate them with efficacy end-points using non-parametric test.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Biliary Cancer</condition>
  <arm_group>
    <arm_group_label>IP (irinotecan and cisplatin)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Irinotecan 65mg/m² D1 and D8 q21 days plus Cisplatin 60mg/m² D1 q 21 days, until disease progression or unacceptable toxicity, with standard hydration and antiemetics.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GC (gemcitabine and cisplatin)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Gemcitabine 1000mg/m² D1 and D8 every 21 days plus cisplatin 25mg/m² D1 and D8 every 21 days, until disease progression or unacceptable toxicity, with standard hydration and antiemetics.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <description>Irinotecan 65mg/m² D1 and D8 q21 days, until disease progression or unacceptable toxicity.
Given in association with standard hydration and anti-emetics.</description>
    <arm_group_label>IP (irinotecan and cisplatin)</arm_group_label>
    <other_name>CPT-11</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Cisplatin 60mg/m² D1 q 21 days, until disease progression or unacceptable toxicity.
Given in association with standard hydration and anti-emetics.</description>
    <arm_group_label>IP (irinotecan and cisplatin)</arm_group_label>
    <other_name>CDDP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Cisplatin 25mg/m² D1 and D8 every 21 days, until disease progression or unacceptable toxicity. , with standard hydration and antiemetics.
Given in association with standard hydration and anti-emetics.</description>
    <arm_group_label>GC (gemcitabine and cisplatin)</arm_group_label>
    <other_name>CDDP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Gemcitabine 1000mg/m² D1 and D8 every 21 days, until disease progression or unacceptable toxicity.
Given in association with standard hydration and anti-emetics.</description>
    <arm_group_label>GC (gemcitabine and cisplatin)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  biopsy-proven gallbladder or biliary tract cancer;

          -  Recurrent, metastatic or unresectable disease;

          -  Chemo-naïve.

          -  Not candidates to curative-intent treatment, such as surgery or radiation-therapy;

          -  Measurable disease according to RECIST 1.1;

          -  ECOG 0-2;

          -  Adequate hematologic and biochemistry tests;

          -  Creatinine clearance &gt;= 60ml/min.

        Exclusion Criteria:

          -  Known hypersensibility or previous therapy with cisplatin, gemcitabine or irinotecan;

          -  Chronic immunosuppressive therapy;

          -  Known CNS metastasis;

          -  Previous diagnosis of other cancer;

          -  Chronic or acute active infection, except asymptomatic HIV infection;

          -  Active bleeding;

          -  Any severe medical condition;

          -  Pregnant or lactating women, or with childbearing potential;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lucas V dos Santos, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Barretos Cancer Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kathia C Abdalla, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Barretos Cancer Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joao Paulo S N Lima, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Barretos Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lucas V dos Santos, MD</last_name>
    <phone>+5517-81544670</phone>
    <email>lucasvsantos@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kathia C Abdalla, MD</last_name>
    <phone>+551733216600</phone>
    <phone_ext>6829</phone_ext>
    <email>kathia.abdalla@hcancerbarretos.com.br</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Barretos Cancer Hospital</name>
      <address>
        <city>Barretos</city>
        <state>SP</state>
        <zip>14784400</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lucas V. dos Santos, M.D.</last_name>
      <phone>+551781544670</phone>
      <email>lucasvsantos@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Kathia C Abdalla, MD</last_name>
      <phone>+551733216600</phone>
      <phone_ext>6829</phone_ext>
      <email>kathia.abdalla@hcancerbarretos.com.br</email>
    </contact_backup>
    <investigator>
      <last_name>Kathia C Abdalla, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Arinilda C Bragagnoli, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 14, 2013</study_first_submitted>
  <study_first_submitted_qc>May 21, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 22, 2013</study_first_posted>
  <last_update_submitted>January 17, 2018</last_update_submitted>
  <last_update_submitted_qc>January 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>biliary cancer</keyword>
  <keyword>irinotecan</keyword>
  <keyword>cisplatin</keyword>
  <keyword>gemcitabine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Biliary Tract Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Camptothecin</mesh_term>
    <mesh_term>Antiemetics</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

